Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 01 04:00PM ET
0.9032
Dollar change
-0.0866
Percentage change
-8.75
%
Index- P/E- EPS (ttm)-1.19 Insider Own8.52% Shs Outstand114.92M Perf Week9.20%
Market Cap102.76M Forward P/E- EPS next Y-0.68 Insider Trans-15.41% Shs Float114.06M Perf Month2.52%
Income-89.91M PEG- EPS next Q-0.26 Inst Own54.17% Short Float15.44% Perf Quarter3.70%
Sales145.67M P/S0.71 EPS this Y40.57% Inst Trans11.63% Short Ratio24.58 Perf Half Y-20.07%
Book/sh-1.06 P/B- EPS next Y9.04% ROA-35.14% Short Interest17.61M Perf Year14.88%
Cash/sh1.34 P/C0.68 EPS next 5Y- ROE- 52W Range0.62 - 1.95 Perf YTD4.42%
Dividend Est.- P/FCF- EPS past 5Y16.79% ROI-149.99% 52W High-53.68% Beta0.15
Dividend TTM- Quick Ratio3.56 Sales past 5Y52.21% Gross Margin95.81% 52W Low46.29% ATR (14)0.07
Dividend Ex-Date- Current Ratio3.62 EPS Y/Y TTM45.95% Oper. Margin-89.89% RSI (14)55.77 Volatility13.28% 7.03%
Employees325 Debt/Eq- Sales Y/Y TTM-0.23% Profit Margin-61.72% Recom1.57 Target Price4.36
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q30.63% Payout- Rel Volume2.37 Prev Close0.99
Sales Surprise18.16% EPS Surprise32.86% Sales Q/Q13.86% EarningsNov 05 BMO Avg Volume716.73K Price0.90
SMA204.95% SMA5012.52% SMA200-11.79% Trades Volume1,697,330 Change-8.75%
Date Action Analyst Rating Change Price Target Change
Jan-19-23Initiated Piper Sandler Overweight $8
Nov-04-22Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $10
Feb-09-22Upgrade JP Morgan Underweight → Neutral $8
Nov-19-21Resumed Morgan Stanley Equal-Weight $27 → $10
Aug-06-21Downgrade SVB Leerink Outperform → Mkt Perform $6
Aug-06-21Downgrade RBC Capital Mkts Outperform → Sector Perform $17 → $8
Aug-06-21Downgrade JP Morgan Overweight → Neutral
Jul-02-20Initiated Morgan Stanley Overweight $34
Mar-04-20Initiated Barclays Overweight $30
Jan-17-20Downgrade Wedbush Outperform → Neutral
Nov-01-24 04:05PM
Oct-31-24 10:02AM
08:00AM
07:30AM
Oct-30-24 04:30PM
01:01PM Loading…
Oct-25-24 01:01PM
Oct-17-24 10:35PM
Oct-01-24 04:05PM
Sep-23-24 05:00AM
Sep-05-24 09:35AM
Sep-03-24 04:05PM
07:00AM
Sep-02-24 05:52AM
Aug-07-24 02:56AM
Aug-06-24 10:30PM
09:25AM Loading…
09:25AM
08:21AM
07:30AM
Aug-01-24 04:05PM
Jul-31-24 04:05PM
Jul-24-24 11:24PM
Jul-15-24 10:56AM
Jul-05-24 09:10AM
Jul-01-24 04:05PM
Jun-26-24 04:42AM
Jun-03-24 04:05PM
Jun-01-24 01:45PM
May-29-24 04:05PM
May-23-24 06:45AM
May-09-24 11:10AM
03:02AM Loading…
03:02AM
May-08-24 10:36PM
04:45PM
04:05PM
12:54PM
09:12AM
07:41AM
07:30AM
07:30AM
May-02-24 04:30PM
May-01-24 04:05PM
Apr-24-24 04:01PM
Apr-01-24 04:05PM
Mar-06-24 04:05PM
Mar-04-24 11:53PM
Mar-01-24 04:05PM
09:21AM
Feb-29-24 10:03PM
06:15PM
08:40AM
07:50AM
07:30AM
Feb-25-24 01:37PM
Feb-22-24 07:00AM
Feb-14-24 10:00AM
Feb-01-24 04:05PM
Jan-08-24 08:30AM
Jan-03-24 07:00AM
Jan-02-24 04:05PM
Dec-13-23 08:47PM
Dec-10-23 08:15PM
Dec-06-23 04:00AM
Dec-01-23 04:05PM
Nov-08-23 04:05PM
Nov-06-23 07:00AM
Nov-03-23 12:46PM
Nov-02-23 03:30PM
09:33AM
09:20AM
07:47AM
07:30AM
Oct-30-23 08:00AM
Oct-26-23 07:00AM
Oct-02-23 04:05PM
Sep-26-23 07:00AM
Sep-05-23 04:05PM
Sep-01-23 04:05PM
08:00AM
Aug-17-23 08:44AM
Aug-03-23 02:18PM
Aug-02-23 02:00PM
08:45AM
07:37AM
07:30AM
Aug-01-23 04:05PM
Jul-26-23 07:00AM
Jul-25-23 03:00PM
Jul-19-23 08:00AM
Jul-17-23 04:05PM
Jul-05-23 04:05PM
12:00PM
Jun-28-23 08:00AM
Jun-08-23 07:40AM
Jun-01-23 04:05PM
07:00AM
May-23-23 04:05PM
May-09-23 02:59PM
May-05-23 06:07AM
May-04-23 04:09PM
01:00PM
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paulson Richard A.President and CEOOct 04 '24Sale0.883,6073,1721,135,607Oct 07 04:44 PM
Mano MichaelSVP, General Counsel&SecretarySep 04 '24Sale0.723,9712,866273,881Sep 05 04:28 PM
Paulson Richard A.President and CEOSep 04 '24Sale0.723,6672,6471,139,214Sep 05 04:26 PM
Mason MichaelEVP, CFO & TreasurerSep 04 '24Sale0.727,0505,089391,054Sep 05 04:24 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerSep 04 '24Sale0.725,3563,866404,051Sep 05 04:13 PM
Paulson Richard A.President and CEOAug 06 '24Sale0.933,6083,3551,142,881Aug 08 04:31 PM
Poulton StuartEVP, Chief Development OfficerJul 30 '24Sale1.062,8833,056326,628Jul 31 04:14 PM
Paulson Richard A.President and CEOJul 05 '24Sale0.853,6163,0771,146,489Jul 09 04:15 PM
PAKIANATHAN DEEPIKADirectorJun 05 '24Sale0.96468,044448,4803,385Jun 07 07:18 PM
PAKIANATHAN DEEPIKADirectorJun 07 '24Sale0.95231,548220,1330Jun 07 07:18 PM
PAKIANATHAN DEEPIKADirectorJun 06 '24Sale0.98118,452116,4152,240Jun 07 07:18 PM
Mason MichaelEVP, CFO & TreasurerJun 04 '24Sale0.99652645398,104Jun 06 04:03 PM
Paulson Richard A.President and CEOJun 04 '24Sale0.993,5923,5561,150,105Jun 06 04:02 PM
PAKIANATHAN DEEPIKADirectorJun 03 '24Sale1.00360,744360,99711,209Jun 04 06:51 PM
PAKIANATHAN DEEPIKADirectorJun 04 '24Sale0.95341,040324,7047,911Jun 04 06:51 PM
PAKIANATHAN DEEPIKADirectorMay 31 '24Sale0.95204,394194,99214,697Jun 04 06:51 PM
Paulson Richard A.President and CEOMay 06 '24Sale1.133,5764,0411,153,697May 07 04:56 PM
Rangwala ReshmaEVP & Chief Medical OfficerApr 22 '24Sale1.176,7897,943342,931Apr 23 04:02 PM
Paulson Richard A.President and CEOApr 04 '24Sale1.293,5634,5961,157,273Apr 05 05:20 PM
Paulson Richard A.President and CEOMar 05 '24Sale1.303,5734,6451,160,836Mar 06 04:14 PM
Rangwala ReshmaEVP & Chief Medical OfficerFeb 29 '24Sale1.1715,66718,330355,689Mar 04 07:41 PM
Rangwala ReshmaEVP & Chief Medical OfficerMar 01 '24Sale1.205,9697,163349,720Mar 04 07:41 PM
Poulton StuartEVP, Chief Development OfficerFeb 29 '24Sale1.1716,31119,084335,666Mar 04 07:40 PM
Poulton StuartEVP, Chief Development OfficerMar 01 '24Sale1.206,1557,386329,511Mar 04 07:40 PM
Mason MichaelEVP, CFO & TreasurerFeb 29 '24Sale1.1727,68732,394404,918Mar 04 07:39 PM
Mason MichaelEVP, CFO & TreasurerMar 01 '24Sale1.206,1627,394398,756Mar 04 07:39 PM
Mano MichaelSVP, General Counsel&SecretaryFeb 29 '24Sale1.1716,97319,858281,428Mar 04 07:38 PM
Mano MichaelSVP, General Counsel&SecretaryMar 01 '24Sale1.203,5764,291277,852Mar 04 07:38 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerFeb 29 '24Sale1.1721,84025,553398,618Mar 04 07:37 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerMar 01 '24Sale1.205,1096,131393,509Mar 04 07:37 PM
Paulson Richard A.President and CEOFeb 29 '24Sale1.1780,47094,1501,183,783Mar 04 07:36 PM
Paulson Richard A.President and CEOMar 01 '24Sale1.2019,37423,2491,164,409Mar 04 07:36 PM
Mason MichaelEVP, CFO & TreasurerFeb 27 '24Sale1.322,5453,369244,400Feb 29 05:35 PM
Poulton StuartEVP, Chief Development OfficerFeb 15 '24Sale1.335,8477,783163,772Feb 20 04:59 PM
Mason MichaelEVP, CFO & TreasurerFeb 06 '24Sale1.594,2056,671246,945Feb 08 04:36 PM
Paulson Richard A.President and CEOFeb 06 '24Sale1.594,0126,365821,453Feb 08 04:34 PM
Paulson Richard A.President and CEOJan 04 '24Sale0.824,1143,373783,465Jan 08 09:00 PM
Paulson Richard A.President and CEODec 04 '23Sale0.793,6222,861787,579Dec 05 05:03 PM
Paulson Richard A.President and CEONov 06 '23Sale0.923,6063,319791,201Nov 07 05:32 PM